Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced the termination, for material breach, of the agreement with Circassia Pharmaceuticals, PLC for licensing the commercial rights for LungFit™ PH in the United States and China for use in the hospital setting at NO concentrations < 80 ppm. The agreement was signed January 23, 2019.
Beyond Air is evaluating options for the commercialization of LungFit™ PH, which is still on track for the second half of 2020 in the United States.
For more information, visit www.beyondair.net.
Case Study: How NYU Langone Rebuilt for Resilience After Superstorm Sandy
Frederick Health Hospital Faces 5 Lawsuits Following Ransomware Attack
Arkansas Methodist Medical Center and Baptist Memorial Health Care to Merge
Ground Broken on Intermountain Saratoga Springs Multi-Specialty Clinic
Electrical Fire Tests Resilience of Massachusetts Hospital